Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1996 Aug;59(2):331–342.

Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

M H Ruttledge 1, A A Andermann 1, C M Phelan 1, J O Claudio 1, F Y Han 1, N Chretien 1, S Rangaratnam 1, M MacCollin 1, P Short 1, D Parry 1, V Michels 1, V M Riccardi 1, R Weksberg 1, K Kitamura 1, J M Bradburn 1, B D Hall 1, P Propping 1, G A Rouleau 1
PMCID: PMC1914741  PMID: 8755919

Abstract

The gene predisposing to neurofibromatosis type 2 (NF2) on human chromosome 22 has revealed a wide variety of different mutations in NF2 individuals. These patients display a marked variability in clinical presentation, ranging from very severe disease with numerous tumors at a young age to a relatively mild condition much later in life. To investigate whether this phenotypic heterogeneity is determined by the type of mutation in NF2, we have collected clinical information on 111 NF2 cases from 73 different families on whom we have performed mutation screening in this gene. Sixty-seven individuals (56.2%) from 41 of these kindreds revealed 36 different putative disease-causing mutations. These include 26 proposed protein-truncating alterations (frameshift deletions/insertions and nonsense mutations), 6 splice-site mutations, 2 missense mutations, 1 base substitution in the 3' UTR of the NF2 cDNA, and a single 3-bp in-frame insertion. Seventeen of these mutations are novel, whereas the remaining 19 have been described previously in other NF2 individuals or sporadic tumors. When individuals harboring protein-truncating mutations are compared with cases with single codon alterations, a significant correlation (P < .001) with clinical outcome is observed. Twenty-four of 28 patients with mutations that cause premature truncation of the NF2 protein, schwannomin, present with severe phenotypes. In contrast, all 16 cases from three families with mutations that affect only a single amino acid have mild NF2. These data provide conclusive evidence that a phenotype/genotype correlation exists for certain NF2 mutations.

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bourn D., Carter S. A., Evans D. G., Goodship J., Coakham H., Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet. 1994 Jul;55(1):69–73. [PMC free article] [PubMed] [Google Scholar]
  2. Bourn D., Carter S. A., Mason S., Gareth D., Evans R., Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet. 1994 May;3(5):813–816. doi: 10.1093/hmg/3.5.813. [DOI] [PubMed] [Google Scholar]
  3. Eldridge R. Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol. 1981;29:57–65. [PubMed] [Google Scholar]
  4. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Strachan T., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992 Dec;29(12):847–852. doi: 10.1136/jmg.29.12.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaiser-Kupfer M. I., Freidlin V., Datiles M. B., Edwards P. A., Sherman J. L., Parry D., McCain L. M., Eldridge R. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol. 1989 Apr;107(4):541–544. doi: 10.1001/archopht.1989.01070010555030. [DOI] [PubMed] [Google Scholar]
  7. Kanter W. R., Eldridge R., Fabricant R., Allen J. C., Koerber T. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980 Aug;30(8):851–859. doi: 10.1212/wnl.30.8.851. [DOI] [PubMed] [Google Scholar]
  8. MacCollin M., Mohney T., Trofatter J., Wertelecki W., Ramesh V., Gusella J. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA. 1993 Nov 17;270(19):2316–2320. doi: 10.1001/jama.270.19.2316. [DOI] [PubMed] [Google Scholar]
  9. Martuza R. L., Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988 Mar 17;318(11):684–688. doi: 10.1056/NEJM198803173181106. [DOI] [PubMed] [Google Scholar]
  10. Mérel P., Hoang-Xuan K., Sanson M., Bijlsma E., Rouleau G., Laurent-Puig P., Pulst S., Baser M., Lenoir G., Sterkers J. M. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. doi: 10.1002/gcc.2870120206. [DOI] [PubMed] [Google Scholar]
  11. Narod S. A., Parry D. M., Parboosingh J., Lenoir G. M., Ruttledge M., Fischer G., Eldridge R., Martuza R. L., Frontali M., Haines J. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet. 1992 Sep;51(3):486–496. [PMC free article] [PubMed] [Google Scholar]
  12. Pastores G. M., Michels V. V., Jack C. R., Jr Early childhood diagnosis of acoustic neuromas in presymptomatic individuals at risk for neurofibromatosis 2. Am J Med Genet. 1991 Dec 1;41(3):325–329. doi: 10.1002/ajmg.1320410313. [DOI] [PubMed] [Google Scholar]
  13. Pearson-Webb M. A., Kaiser-Kupfer M. I., Eldridge R. Eye findings in bilateral acoustic (central) neurofibromatosis: association with presenile lens opacities and cataracts but absence of Lisch nodules. N Engl J Med. 1986 Dec 11;315(24):1553–1554. doi: 10.1056/NEJM198612113152419. [DOI] [PubMed] [Google Scholar]
  14. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  15. Rouleau G. A., Seizinger B. R., Wertelecki W., Haines J. L., Superneau D. W., Martuza R. L., Gusella J. F. Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Am J Hum Genet. 1990 Feb;46(2):323–328. [PMC free article] [PubMed] [Google Scholar]
  16. Rouleau G. A., Wertelecki W., Haines J. L., Hobbs W. J., Trofatter J. A., Seizinger B. R., Martuza R. L., Superneau D. W., Conneally P. M., Gusella J. F. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. doi: 10.1038/329246a0. [DOI] [PubMed] [Google Scholar]
  17. Ruttledge M. H., Narod S. A., Dumanski J. P., Parry D. M., Eldridge R., Wertelecki W., Parboosingh J., Faucher M. C., Lenoir G. M., Collins V. P. Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology. 1993 Sep;43(9):1753–1760. doi: 10.1212/wnl.43.9.1753. [DOI] [PubMed] [Google Scholar]
  18. Ruttledge M. H., Sarrazin J., Rangaratnam S., Phelan C. M., Twist E., Merel P., Delattre O., Thomas G., Nordenskjöld M., Collins V. P. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994 Feb;6(2):180–184. doi: 10.1038/ng0294-180. [DOI] [PubMed] [Google Scholar]
  19. Ruttledge M. H., Xie Y. G., Han F. Y., Giovannini M., Janson M., Fransson I., Werelius B., Delattre O., Thomas G., Evans G. Physical mapping of the NF2/meningioma region on human chromosome 22q12. Genomics. 1994 Jan 1;19(1):52–59. doi: 10.1006/geno.1994.1012. [DOI] [PubMed] [Google Scholar]
  20. Seizinger B. R., Rouleau G., Ozelius L. J., Lane A. H., St George-Hyslop P., Huson S., Gusella J. F., Martuza R. L. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science. 1987 Apr 17;236(4799):317–319. doi: 10.1126/science.3105060. [DOI] [PubMed] [Google Scholar]
  21. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  22. Wertelecki W., Rouleau G. A., Superneau D. W., Forehand L. W., Williams J. P., Haines J. L., Gusella J. F. Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med. 1988 Aug 4;319(5):278–283. doi: 10.1056/NEJM198808043190505. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES